Vikram Kansra

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

David Gardiner, Jay Lalezari, Eric Lawitz et al. · PLoS ONE · 2013 · 227 citations · Full text

A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization

Roberto D. Polakiewicz, Sandra M. Schieferl, Lydia F. Dorner et al. · Journal of Biological Chemistry · 1998 · 143 citations · Full text

Molecular Pain, Pharmacotherapy, Mapk Cascade +19

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

Bernardo L. Rapoport, Martin Chasen, Cesare Gridelli et al. · The Lancet Oncology · 2015 · 139 citations

Emetogenic Chemotherapy, Chemotherapy-induced Nausea, Gastrointestinal Oncology +7

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Marjorie G. Zauderer, Peter W. Szlosarek, Sylvestre Le Moulec et al. · The Lancet Oncology · 2022 · 119 citations

Ezh2 Inhibitor Tazemetostat, Malignant Disease, Medicine +7

Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut

Jason P. Lynch, Coral González-Prieto, Analise Z. Reeves et al. · Cell Host & Microbe · 2023 · 115 citations · Full text

Engineering, Situ Secretion, Nanobiotechnology +8